文献速递肿瘤 PET/CT

[18F]F-ATD001与[18F]FDG PET/CT在三阴性乳腺癌中的病灶检出与摄取模式比较

Lesion Detection and Uptake Patterns of [18F]F-ATD001 PET/CT and [18F]FDG PET/CT in Triple-Negative Breast Cancer.
PubMed 文献 · J Nucl Med · 2026-09-10

本研究纳入37例组织学确诊的三阴性乳腺癌女性患者,比较PARP靶向示踪剂[18F]F-ATD001与标准[18F]FDG PET/CT的摄取特征及病灶检出模式。结果显示[18F]F-ATD001在各恶性部位的半定量参数均低于[18F]FDG,但两种示踪剂在部位水平的病灶检出率无统计学显著差异,原发灶SUVmax呈中度相关,其他部位相关性较弱。提示[18F]F-ATD001 PET/CT可能与[18F]FDG PET/CT在TNBC评估中起互补作用。

要点

  • [18F]F-ATD001在各恶性部位的SUVmax和SUVmean均低于[18F]FDG。
  • 两种示踪剂在部位水平的病灶检出率无统计学显著差异。
  • 原发灶SUVmax呈中度相关,其他部位相关性较弱,提示[18F]F-ATD001可能互补[18F]FDG。

核心结论

  • 在三阴性乳腺癌患者中,[18F]F-ATD001 PET/CT与[18F]FDG PET/CT在部位水平的病灶检出率无统计学显著差异。
  • [18F]F-ATD001摄取值虽低于[18F]FDG,但原发灶呈中度相关,其他部位相关性较弱,提示其可能与[18F]FDG PET/CT起互补作用。

研究设计与样本

  • 纳入37例年龄≥18岁、组织学确诊TNBC且[18F]FDG PET/CT上有可测量病灶的女性患者。
  • 静脉注射[18F]F-ATD001后60分钟行全身PET/CT,并与[18F]FDG PET/CT进行半定量分析和不同部位病灶计数比较。

主要发现

  • 患者平均±SD年龄为45.3±11.73岁(范围23-75岁),32/37(86.5%)为浸润性导管癌非特殊亚型。
  • [18F]F-ATD001在各恶性部位的半定量参数均低于[18F]FDG,原发灶中位SUVmax为3.45对17.63,淋巴结为3.88对10.25。
  • 原发灶SUVmax和SUVmean呈中度相关(Spearman ρ分别为0.39和0.54),其他部位相关性较弱。
  • 两种示踪剂在部位水平的病灶检出率无统计学显著差异。

关键数值与推荐

  • 原发灶[18F]F-ATD001中位SUVmax为3.45,[18F]FDG为17.63。
  • 淋巴结[18F]F-ATD001中位SUVmax为3.88,[18F]FDG为10.25。
  • 原发灶SUVmax的Spearman ρ=0.39,SUVmean的Spearman ρ=0.54。

临床怎么用

  • [18F]F-ATD001 PET/CT可作为PARP表达的无创生物标志物,与[18F]FDG PET/CT互补用于TNBC患者评估。
  • 因[18F]F-ATD001摄取值普遍低于[18F]FDG,判读时应结合两种示踪剂结果而非单独依赖[18F]F-ATD001摄取高低。

局限性

  • 本研究为单中心小样本(37例女性)影像比较,未报告诊断效能、阈值或预后数据。
  • 原文未报告示踪剂剂量、辐射剂量学、重复性及不同阅片者一致性等信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In triple-negative breast cancer (TNBC), the upregulation of poly(adenosine disphosphate-ribose) polymerase (PARP) has afforded an attractive therapeutic target with PARP inhibitors. Improved survival outcomes associated with PARP inhibitors as either monotherapy or adjuvant therapy have been demonstrated in various clinical trials. Because PARP expression may vary between lesions, whole-body PARP-targeted imaging may complement standard-of-care [18F]FDG PET/CT. [18F]F-ATD001, a radiolabeled olaparib PET tracer, is a noninvasive biomarker of in vivo PARP expression. We compared the uptake characteristics and lesion detection patterns of [18F]F-ATD001 PET/CT with those of [18F]FDG PET/CT in patients with TNBC. Methods: Consenting participants aged 18 y or older with histologically confirmed TNBC and measurable disease on [18F]FDG PET/CT were included. Whole-body PET/CT was performed 60 min after intravenous injection of [18F]F-ATD001. Semiquantitative (SUVmax and SUVmean) analysis and numeric counting of lesions at different sites (primary, lymph node, viscera, and skeleton) were performed for both [18F]FDG PET/CT and [18F]F-ATD001 PET/CT images. Site-level detection rates were compared between tracers, and correlations of semiquantitative parameters were assessed. Results: Thirty-seven women with histologically confirmed TNBC underwent both [18F]FDG PET/CT and [18F]F-ATD001 PET/CT. The mean ± SD age was 45.3 ± 11.73 y (range, 23-75 y). Most patients (32/37, 86.5%) had infiltrating ductal carcinoma of no special subtype. Semiquantitative parameters for [18F]F-ATD001 were substantially lower than the corresponding values for [18F]FDG across all malignant sites, with a median SUVmax of 3.45 versus 17.63 in primary lesions and 3.88 versus 10.25 in lymph nodes, respectively. Moderate correlation was observed for SUVmax and SUVmean in primary lesions (Spearman ρ = 0.39 and 0.54, respectively), whereas correlation was weak at other sites. No statistically significant site-level differences in lesion detection rates were observed between [18F]FDG PET/CT and [18F]F-ATD001 PET/CT. Conclusion: In this study of patients with TNBC, no statistically significant site-level differences in lesion detection rates were observed between [18F]F-ATD001 PET/CT and [18F]FDG PET/CT. Despite lower uptake values on [18F]F-ATD001 PET/CT, moderate correlation was observed in primary lesions, with weaker correlation at other sites. These findings suggest that [18F]F-ATD001 PET/CT may have a complementary role with [18F]FDG PET/CT in the evaluation of patients with TNBC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ndlovu H, Lawal IO, Moholisa RR, et al. Lesion Detection and Uptake Patterns of [18F]F-ATD001 PET/CT and [18F]FDG PET/CT in Triple-Negative Breast Cancer. J Nucl Med. 2026. PMID: 42722436. doi:10.2967/jnumed.125.271973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。